Visus Therapeutics
6 articles with Visus Therapeutics
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
11/30/2021
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia.
-
Visus Therapeutics Appoints Ophthalmology Expert David Guyer, M.D., as Chairman of the Board and Welcomes Seasoned Life Sciences Executive Ted Danse as Head of Business Development
11/3/2021
Visus Therapeutics Inc. today announced the appointment of ophthalmology and industry expert David Guyer, M.D. as the chairman of the Board
-
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
8/19/2021
Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.
-
Visus Therapeutics has acquired an additional $20 million in funding to support its mission of developing innovative ophthalmic therapies for people worldwide.
-
Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop
3/9/2021
Visus Therapeutics Inc. today announced the close of a $36 million Series A Preferred Stock financing. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders